Multivariate analysis of PM double PET and MFC negativity for PFS and OS in patients treated with daratumumab
| . | HR . | 95% CI . | P value . |
|---|---|---|---|
| PFS | |||
| PM double MFC and PET negativity | 0.39 | 0.23-0.67 | .0006 |
| R-ISS, III | 2.04 | 0.87-4.78 | .099 |
| OS | |||
| PM double MFC and PET negativity | 0.47 | 0.17-1.23 | .13 |
| R-ISS, III | 6.08 | 2.10-17.61 | .0009 |
| . | HR . | 95% CI . | P value . |
|---|---|---|---|
| PFS | |||
| PM double MFC and PET negativity | 0.39 | 0.23-0.67 | .0006 |
| R-ISS, III | 2.04 | 0.87-4.78 | .099 |
| OS | |||
| PM double MFC and PET negativity | 0.47 | 0.17-1.23 | .13 |
| R-ISS, III | 6.08 | 2.10-17.61 | .0009 |